AUTHORS
Kai Lu, Sumedha Roy2, Trine Line Okholm3, Christopher Bolen4, Lijun Yao5, Hayat Elqossari6, Oscar Cazares7, Vipul Bhargava8, Rin Nakamura9, Katerina Hatzi10
AFFILIATIONS
1 Genentech, Inc., South San Francisco, California, United States
2 Genentech, Inc., South San Francisco, California, United States
3 Genentech, Inc., South San Francisco, California, United States
4 Genentech, Inc., South San Francisco, California, United States
5 Genentech, Inc., South San Francisco, California, United States
6 Genentech, Inc., South San Francisco, California, United States
7 Genentech, Inc., South San Francisco, California, United States
8 Genentech, Inc., South San Francisco, California, United States
9 Genentech, Inc., South San Francisco, California, United States
10 Genentech, Inc., South San Francisco, California, United States
ABSTRACT
Background: Despite the success of T-cell engaging (TCE) therapies in multiple myeloma (MM), durable responses are often limited by tumor-intrinsic mechanisms, T-cell dysfunction, and an immunosuppressive tumor microenvironment. CD200 is an inhibitory immune checkpoint highly expressed in >70% of MM cases and associated with poor outcomes, but its role during TCE therapy remains poorly understood. We examined the dynamic role of the CD200-CD200R axis as a mediator of resistance to TCE therapy and assessed if therapeutic outcomes could be enhanced through its blockade.
Methods: Bulk RNA-seq data were generated from baseline bone marrow mononuclear cell (BMMC) specimens prior to cevostamab (FcRH5xCD3 TCE) treatment initiation. We performed single-cell RNA-sequencing (scRNA-seq) and spectral flow cytometry on BMMCs longitudinally collected from MM patients treated with cevostamab. Additionally, publicly available scRNA-seq data from MM patients treated with elranatamab (BCMAxCD3 TCE) were analyzed (Friedrich et al., Cancer Cell, 2023). In vitro and ex vivo killing assays utilizing MM donor peripheral blood mononuclear cells (PBMCs) or primary MM BMMCs co-cultured with parental or engineered CD200 expressing cell lines were conducted to measure the cytotoxicity of various TCEs (targeted to FcRH5, BCMA, CD20, or other solid tumor antigens) alone, and in combination with CD200 blockade. Autologous MM and CLL patient samples were treated ex vivo with TCE alone or in combination with CD200 blockade followed by assessment of T-cell profiles, cytokine secretion, and T-cell cytotoxicity.
Results: Upon interrogating various immunomodulatory molecules, we initially observed that bone marrow bulk RNA-seq CD200 expression in cevostamab clinical specimens at baseline was higher in non-responders (≤PR) compared to responders (≥VGPR). Based on this finding we evaluated the tumor-intrinsic role of CD200 in the context of T-cell bispecific treatment. Preclinical models using TCEs targeting various hematologic or solid tumor antigens showed that CD200 expression on tumor cells intrinsically impaired TCE-mediated cytotoxicity. We noted that while CD200 was not expressed at baseline on CD4 or CD8 T cells, we observed a TCE-mediated CD200 T-cell induction on T cells. This observation was further confirmed from the single-cell transcriptional profiles of BMMC derived T-cells isolated from cevostamab- and elranatamab-treated patients. We found moderate induction and sustained expression of CD200 in subsets of T-cells during, but not prior to therapy, including at relapse. Similarly, spectral flow analysis of BMMC derived T-cells from cevostamab treated patients confirmed upregulated CD200 surface protein expression on BM T-cells.
Next, we explored the potential impact of CD200 blockade on TCE outcomes. Assays using MM patient-derived samples showed that CD200 blockade enhanced FcRH5 TCE and BCMA TCE mediated killing of MM cell lines and increased IFNγ production. This combination increased tumor cell line killing, specifically at low effector-to-target ratios, indicative of improved serial killing capacity among T-cells. Beyond MM, autologous ex vivo assays using primary CLL samples showed that CD200 blockade combined with a CD20 TCE significantly enhanced T-cell mediated killing compared to TCE alone. In summary, these findings suggest that in tandem with its tumor-intrinsic immune evasion properties, the induction of CD200 on T-cells during TCE therapy may act as an immunosuppressive mechanism to mediate TCE resistance.
Conclusion: Collectively, clinical and preclinical data identify the CD200-CD200R signaling axis as a multimodal immune checkpoint associated with resistance to TCE treatment via tumor-intrinsic immune escape and therapy-induced upregulation on T cells. Targeting the CD200-CD200R axis restored effector function and enhanced TCE mediated killing, supporting CD200 blockade as a rational clinical combination strategy to improve T-cell based immunotherapies in MM and potentially additional CD200 expressing tumors.
DISCLOSURES
Kai Lu: Genentech, Inc. - Current Employment